Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $10.00K | $75.00K | $1.16M | $10.16M | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | $899.30K | $275.12K | $263.54K |
| Gross Profit | N/A | $10.00K | $75.00K | $1.16M | $10.16M | $-899.30K | $-275.12K | $-263.54K |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Operating Expenses | $68.76M | $39.29M | $47.48M | $64.61M | $61.67M | $60.49M | $51.23M | $33.67M |
| Operating Income | $-68.76M | $-39.28M | $-47.40M | $-63.45M | $-51.51M | $-61.39M | $-51.51M | $-33.93M |
| Operating Margin | 0.00% | -392752.93% | -63204.43% | -5470.69% | -506.84% | 0.00% | 0.00% | 0.00% |
| Net Income | $-71.47M | $-36.90M | $-46.69M | $-63.43M | $-51.03M | $-54.12M | $-48.27M | $-33.28M |
| Net Margin | 0.00% | -368994.20% | -62251.74% | -5468.98% | -502.09% | 0.00% | 0.00% | 0.00% |
| EPS (Basic) | $-0.59 | $-0.58 | $-0.89 | $-1.23 | $-1.12 | $-1.25 | $-1.18 | $-1.13 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |